Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Aplastic Anemia
Questions discussed in this category
Have you encountered acute kidney injury after starting eltrombopag for aplastic anemia as part of triple immunosuppressive regimen with ATG and cyclosporine?
1 Answer available
When do you refer AYA patients with newly diagnosed severe aplastic anemia for transplant?
Would you give a trial of IST first or immediately refer for SCT if the patient has matched siblings?
2 Answers available
How do you manage prophylactic antimicrobial medications in patients who undergo ATG/cyclosporine/eltrombopag induction for severe aplastic anemia?
What would you recommend within the first year after ATG and thereafter if still maintained on cyclosporine?
1 Answer available
How soon do you anticipate response to cyclosporine in red cell aplasia and what cyclosporine trough levels do you target?
1 Answer available
In what situations do you recommend upfront haploidentical transplant in a pediatric patient with newly diagnosed idiopathic severe aplastic anemia who does not have a MSD/MUD donor?
1 Answer available
How would you approach immunosuppression for patients with severe aplastic anemia who are not transplant or ATG candidates?
Such as patients who are frail, elderly, renally impaired? Would you consider sirolimus over cyclosporine or tacrolimus for safer nephrotoxicity prof...
1 Answer available
Would you stop current immunosuppressive therapy or delay starting immunosuppressive therapy in a patient with aplastic anemia who has been infected with COVID-19?
2 Answers available
16508
9377
9376
13284
12049
10302
6950
Papers discussed in this category
Blood, 2013 Sep 19
Management of the refractory aplastic anemia patient: what are the options?
The Lancet. Haematology, 2015-09
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.
Haematologica, 2017-07
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia.
Related Topics
Internal Medicine
Hematology
Pediatric Hematology/Oncology
Pediatric Hematology
Medical Oncology
Benign Hematology
Bone Marrow Transplant
COVID-19
Bone Marrow Failure
Geriatrics Oncology